Risperidone is under clinical development by Valiseek and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Risperidone’s likelihood of approval (LoA) and phase transition for Lung Adenocarcinoma took place on 06 Jun 2022, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway and decreased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Risperidone Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Risperidone overview

Risperidone (VAL-401) is under development for the treatment of metastatic non-small cell lung adenocarcinoma, prostate cancer, pancreatic cancer, and breast cancer. The drug candidate is formulated as liquid lipid-filled capsule and administered through oral route. The drug candidate acts by targeting hydroxysteroid 17-beta dehydrogenase 10 (HSD17B10) or (HSD10)

Quick View Risperidone LOA Data

Report Segments
  • Innovator
Drug Name
  • Risperidone
Administration Pathway
  • Oral
Therapeutic Areas
  • Oncology
Key Developers
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.